MedCap (MCAPS) Stock Overview
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MCAPS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MedCap AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 500.50 |
| 52 Week High | SEK 649.00 |
| 52 Week Low | SEK 493.50 |
| Beta | 0.52 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 205.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCAPS | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 2.1% |
| 1Y | n/a | 8.1% | 23.9% |
Return vs Industry: Insufficient data to determine how MCAPS performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how MCAPS performed against the UK Market.
Price Volatility
| MCAPS volatility | |
|---|---|
| MCAPS Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 11.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: MCAPS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine MCAPS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 592 | Anders Dahlberg | medcap.se/en/ |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe.
MedCap AB (publ) Fundamentals Summary
| MCAPS fundamental statistics | |
|---|---|
| Market cap | SEK 7.18b |
| Earnings (TTM) | SEK 219.80m |
| Revenue (TTM) | SEK 2.11b |
Is MCAPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCAPS income statement (TTM) | |
|---|---|
| Revenue | SEK 2.11b |
| Cost of Revenue | SEK 871.90m |
| Gross Profit | SEK 1.24b |
| Other Expenses | SEK 1.02b |
| Earnings | SEK 219.80m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | 14.63 |
| Gross Margin | 58.64% |
| Net Profit Margin | 10.43% |
| Debt/Equity Ratio | 14.8% |
How did MCAPS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/20 20:18 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedCap AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Hans Mähler | Nordea Markets |